Compare WHG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | WHG | MDXH |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9M | 167.8M |
| IPO Year | 2002 | 2021 |
| Metric | WHG | MDXH |
|---|---|---|
| Price | $18.26 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 12.6K | ★ 126.0K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 154.57 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | $96,243,000.00 | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | 4.20 | ★ 21.68 |
| 52 Week Low | $13.49 | $1.35 |
| 52 Week High | $18.97 | $5.33 |
| Indicator | WHG | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 71.62 | 34.58 |
| Support Level | $16.12 | $3.10 |
| Resistance Level | $18.47 | $3.40 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 0.22 | -0.00 |
| Stochastic Oscillator | 96.64 | 16.41 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.